8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 8, 2026·SEC
Cellectar Biosciences, Inc.(CLRB)Earnings, Financials & Key Ratios
CLRB•NASDAQ
Price updated Jun 19, 2026
AboutCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Show more
- Revenue$0
- EBITDA-$23M+55.8%
- Net Income-$22M+51.1%
- EPS (Diluted)-8.35+80.1%
- ROE-179.99%+99.0%
CLRB Key Insights
Cellectar Biosciences, Inc. (CLRB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLRB Price & Volume
Cellectar Biosciences, Inc. (CLRB) stock price & volume — 10-year historical chart
Loading chart...
CLRB Growth Metrics
Cellectar Biosciences, Inc. (CLRB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM15.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM67.34%
Return on Capital
10 Years-507.81%
5 Years-1014.1%
3 Years-1934.32%
Last Year-174.65%
CLRB Peer Comparison
Cellectar Biosciences, Inc. (CLRB) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTC | 41.78M | 17.31 | -0.38 | -3.5% | -6.25% | -16.12% | 0.06 | |
 RNAC | 282.94M | 9.63 | -1.92 | -92.81% | -85.51% | |||
 RMD | 27.48B | 188.63 | 19.83 | 9.84% | 27.44% | 24.41% | 0.14 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 MRKR | 14.36M | 1.33 | -1.68 | -100% | -5.2% | -0% | ||
 CLDX | 2.16B | 32.43 | -8.32 | -78.63% | -345.96% | -50.72% | 0.00 | |
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 |
Compare CLRB vs Peers
Cellectar Biosciences, Inc. (CLRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLRB Income Statement
Cellectar Biosciences, Inc. (CLRB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 1.55M | 82.27K | 189.36K | 0 | 0 | 0 | 0 | 0 | 213.6K | -110.02K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -1.55M▲ 0% | -82.27K▲ 94.7% | -189.36K▼ 130.2% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -213.6K▲ 0% | 110.02K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -333.47% | 94.68% | -130.18% | 100% | - | - | - | - | - | - |
Operating Expenses | 13.6M | 11.66M | 13.99M | 15.29M | 24.13M | 28.81M | 38.96M | 51.78M | 22.77M | 22.48M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 4.14M | 4.82M | 4.99M | 5.15M | 6.54M | 9.59M | 11.69M | 25.64M | 11.48M | 11.4M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 9.47M | 6.84M | 9M | 10.14M | 17.59M | 19.22M | 27.27M | 26.14M | 11.5M | 11.08M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -213.6K | 0 |
Operating Income | -13.6M▲ 0% | -13.33M▲ 2.0% | -14.18M▼ 6.4% | -15.29M▼ 7.8% | -24.13M▼ 57.8% | -28.81M▼ 19.4% | -38.96M▼ 35.2% | -51.78M▼ 32.9% | -22.98M▲ 55.6% | -22.37M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -43.93% | 1.99% | -6.36% | -7.84% | -57.82% | -19.4% | -35.22% | -32.9% | 55.62% | - |
EBITDA | -12.05M | -13.25M | -13.99M | -15.08M | -23.98M | -28.67M | -38.77M | -51.49M | -22.77M | -22.33M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -32.57% | -9.9% | -5.59% | -7.81% | -59% | -19.53% | -35.24% | -32.8% | 55.78% | 51.38% |
D&A (Non-Cash Add-back) | 1.55M | 82.27K | 189.36K | 207.93K | 149.91K | 148.44K | 192.38K | 291.65K | 213.6K | 47.28K |
EBIT | -13.6M | -13.24M | -14.09M | -15.09M | -24.13M | -28.81M | -38.96M | -51.78M | -22.98M | -22.37M |
Net Interest Income | 0 | 0 | 42.71K | 10.9K | 2.28K | 152.52K | 387.15K | 1.21M | 435.1K | 361.13K |
Interest Income | 0 | 0 | 42.71K | 10.9K | 2.28K | 152.52K | 387.15K | 1.21M | 435.1K | 361.13K |
Interest Expense | 16.61K | 29.69K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 38.68K | -1.58M | 85.71K | 196.18K | 8.92K | -3.04M | -3.87M | 7.26M | 1.19M | 1.53M |
Pretax Income | -13.56M▲ 0% | -13.24M▲ 2.4% | -14.09M▼ 6.4% | -15.09M▼ 7.1% | -24.12M▼ 59.8% | -31.85M▼ 32.0% | -42.83M▼ 34.5% | -44.52M▼ 3.9% | -21.79M▲ 51.0% | -20.84M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | -60K | -60K | 66K | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.19% | 0.14% | -0.15% | 0% | 0% |
Net Income | -13.56M▲ 0% | -13.24M▲ 2.4% | -14.09M▼ 6.4% | -15.09M▼ 7.1% | -24.12M▼ 59.8% | -31.79M▼ 31.8% | -42.77M▼ 34.5% | -44.58M▼ 4.2% | -21.79M▲ 51.1% | -20.84M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -119.44% | 2.38% | -6.45% | -7.1% | -59.81% | -31.8% | -34.53% | -4.23% | 51.12% | 15.09% |
Net Income (Continuing) | -13.56M | -13.24M | -14.09M | -15.09M | -24.12M | -31.79M | -42.77M | -44.58M | -21.79M | -20.84M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3210.00▲ 0% | -1567.96▲ 51.2% | -550.86▲ 64.9% | -228.55▲ 58.5% | -130.35▲ 43.0% | -135.18▼ 3.7% | -104.99▲ 22.3% | -41.89▲ 60.1% | -8.35▲ 80.1% | -4.92▲ 0% |
EPS Growth % | 50% | 51.15% | 64.87% | 58.51% | 42.97% | -3.7% | 22.33% | 60.1% | 80.07% | 67.34% |
EPS (Basic) | -3210.00 | -1567.96 | -550.86 | -228.55 | -130.35 | -135.18 | -104.99 | -36.52 | -8.35 | - |
Diluted Shares Outstanding | 4.68K | 9.87K | 25.58K | 66.04K | 185.05K | 235.19K | 407.38K | 1.24M | 2.61M | 4.24M |
Basic Shares Outstanding | 4.68K | 9.87K | 25.58K | 66.04K | 185.05K | 235.19K | 407.38K | 1.22M | 2.61M | 4.24M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLRB Balance Sheet
Cellectar Biosciences, Inc. (CLRB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 10.47M | 13.95M | 11.39M | 57.94M | 36.57M | 20.53M | 10.45M | 24.25M | 14.04M | 9.27M |
Cash & Short-Term Investments | 10.01M | 13.26M | 10.61M | 57.17M | 35.7M | 19.87M | 9.56M | 23.29M | 13.2M | 8.35M |
Cash Only | 10.01M | 13.26M | 10.61M | 57.17M | 35.7M | 19.87M | 9.56M | 23.29M | 13.2M | 8.35M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 55K | 55K | 0 | 0 | 0 | 663.24K | 888.23K | 961.66K | 842.43K | 920.04K |
Total Non-Current Assets | 1.93M | 1.1M | 865.14K | 719.56K | 630.35K | 1.06M | 1.62M | 1.22M | 939.86K | 1.85M |
Property, Plant & Equipment | 244.71K | 543.34K | 783.92K | 638.35K | 549.13K | 978.98K | 1.59M | 1.19M | 910.08K | 1.82M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 1.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 11.87K | 558.91K | 81.21K | 81.21K | 81.21K | 81.21K | 29.78K | 29.78K | 29.78K | 29.78K |
Total Assets | 12.87M▲ 0% | 15.05M▲ 17.0% | 12.25M▼ 18.6% | 58.66M▲ 378.8% | 37.2M▼ 36.6% | 21.59M▼ 42.0% | 12.08M▼ 44.1% | 25.47M▲ 111.0% | 14.98M▼ 41.2% | 11.12M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -16.01% | 16.96% | -18.62% | 378.82% | -36.58% | -41.97% | -44.07% | 110.96% | -41.2% | -186.06% |
Total Current Liabilities | 2.11M | 1.62M | 2.77M | 3.56M | 3.99M | 11.5M | 25.36M | 9.39M | 4.75M | 4.87M |
Accounts Payable | 1.87M | 1.54M | 1.28M | 1.43M | 1.42M | 2.56M | 5.62M | 4.11M | 1.44M | 4.72M |
Days Payables Outstanding | 440.95 | 6.85K | 2.46K | - | - | - | - | - | 2.46K | -14.8K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100.19K | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 243.99K | 76.09K | 990.87K | 0 | 1.94M | 7.98M | 17.61M | 4.59M | 3.21M | 149K |
Current Ratio | 4.95x | 8.60x | 4.11x | 16.26x | 9.16x | 1.78x | 0.41x | 2.58x | 2.96x | 1.90x |
Quick Ratio | 4.95x | 8.60x | 4.11x | 16.26x | 9.16x | 1.78x | 0.41x | 2.58x | 2.96x | 1.90x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 2.21K | 171K | 421.64K | 301.74K | 166.29K | 552.98K | 494K | 1.79M | 309.4K | 1.53M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 2.21K | 0 | 421.64K | 301.74K | 166.29K | 552.98K | 494K | 409.59K | 309.4K | 2.54M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 171K | 0 | 0 | 0 | 0 | 0 | 1.38M | 0 | 0 |
Total Liabilities | 2.12M | 1.79M | 3.19M | 3.86M | 4.16M | 12.05M | 25.85M | 11.18M | 5.06M | 6.4M |
Total Debt | 5.25K | 2.21K | 527.53K | 421.64K | 301.74K | 603.83K | 552.98K | 494K | 409.59K | 1.53M |
Net Debt | -10M | -13.25M | -10.09M | -56.74M | -35.4M | -19.26M | -9.01M | -22.79M | -12.79M | -6.82M |
Debt / Equity | 0.00x | 0.00x | 0.06x | 0.01x | 0.01x | 0.06x | - | 0.03x | 0.04x | 0.32x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.31x |
Interest Coverage | -819.09x | -445.95x | - | - | - | - | - | - | - | - |
Total Equity | 10.75M▲ 0% | 13.26M▲ 23.3% | 9.06M▼ 31.7% | 54.79M▲ 504.8% | 33.05M▼ 39.7% | 9.54M▼ 71.1% | -13.78M▼ 244.5% | 14.29M▲ 203.8% | 9.92M▼ 30.6% | 4.72M▲ 0% |
Equity Growth % | -20.57% | 23.31% | -31.68% | 504.84% | -39.69% | -71.14% | -244.48% | 203.76% | -30.61% | -157.35% |
Book Value per Share | 2299.44 | 1343.15 | 354.12 | 829.69 | 178.57 | 40.54 | -33.82 | 11.55 | 3.80 | 1.11 |
Total Shareholders' Equity | 10.75M | 13.26M | 9.06M | 54.79M | 33.05M | 9.54M | -13.78M | 14.29M | 9.92M | 4.72M |
Common Stock | 167 | 47 | 94 | 454 | 611 | 94 | 207 | 461 | 42 | 42 |
Retained Earnings | -84.35M | -97.59M | -111.68M | -126.78M | -150.9M | -159.99M | -202.76M | -247.34M | -269.13M | -274.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLRB Cash Flow Statement
Cellectar Biosciences, Inc. (CLRB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -11.02M | -11.44M | -11.69M | -13.93M | -22.57M | -25.22M | -32.38M | -47.58M | -23.12M | -18.58M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -33.06% | -3.83% | -2.2% | -19.15% | -61.98% | -11.76% | -28.37% | -46.97% | 51.41% | 225.74% |
Net Income | -13.56M | -13.24M | -14.09M | -15.09M | -24.12M | -28.6M | -42.77M | -44.58M | -21.79M | -20.84M |
Depreciation & Amortization | 1.55M | 82.27K | 132.8K | 141.45K | 149.91K | 148.44K | 192.38K | 291.65K | 213.6K | 47.28K |
Stock-Based Compensation | 758.76K | 721.21K | 866.79K | 467.54K | 1.12M | 1.45M | 2.41M | 4.27M | 2.26M | 565.39K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -22.07K | 1.56M | 13.56K | -118.8K | 80.66K | 93.82K | 4.32M | -5.84M | -677.5K | 489.69K |
Working Capital Changes | 259.26K | -569.05K | 1.39M | 671.24K | 198.76K | 1.68M | 3.48M | -1.73M | -3.13M | 1.16M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.59M | -3.16M | 46.11K |
Cash from Investing | -346.7K | -329.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K | -9.26K |
Capital Expenditures | -346.7K | -384.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K | 52.03K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -61.29K |
Cash from Financing | 9.93M | 15.02M | 9.02M | 60.55M | 1.25M | 9.61M | 22.94M | 61.41M | 13.03M | 13.03M |
Debt Issued (Net) | -89.32K | -3.04K | -2.21K | 184K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 7.17M | 15.03M | 9.02M | 59.72M | 34.87K | 19.22M | 22.15M | 61.41M | 13.03M | 13.03M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 2.85M | -762 | 0 | 642.5K | 1.21M | -9.61M | 789.64K | 0 | 0 | 0 |
Net Change in Cash | -1.44M▲ 0% | 3.25M▲ 325.9% | -2.7M▼ 183.0% | 46.55M▲ 1826.7% | -21.46M▼ 146.1% | -15.84M▲ 26.2% | -10.3M▲ 35.0% | 13.72M▲ 233.2% | -10.09M▼ 173.5% | -5.56M▲ 0% |
Free Cash Flow | -11.37M▲ 0% | -11.83M▼ 4.0% | -11.72M▲ 0.9% | -14M▼ 19.4% | -22.71M▼ 62.3% | -25.45M▼ 12.1% | -33.24M▼ 30.6% | -47.69M▼ 43.5% | -23.12M▲ 51.5% | -18.59M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -36.06% | -4.05% | 0.92% | -19.43% | -62.27% | -12.06% | -30.62% | -43.46% | 51.51% | 57.45% |
FCF per Share | -2430.40 | -1197.92 | -458.05 | -211.91 | -122.72 | -108.20 | -81.60 | -38.52 | -8.87 | -4.38 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.86x | 0.83x | 0.92x | 0.94x | 0.79x | 0.76x | 1.07x | 1.06x | 0.89x |
Interest Paid | 364 | 0 | 880 | 1.58K | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLRB Key Ratios
Cellectar Biosciences, Inc. (CLRB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -111.65% | -110.25% | -126.28% | -47.28% | -54.92% | -149.33% | - | -17221.69% | -179.99% | -264.79% |
Return on Invested Capital (ROIC) | -693.19% | -2628.14% | - | - | - | - | - | - | - | 619.63% |
Debt / Equity | 0.00x | 0.00x | 0.06x | 0.01x | 0.01x | 0.06x | - | 0.03x | 0.04x | 0.32x |
Interest Coverage | -819.09x | -445.95x | - | - | - | - | - | - | - | - |
FCF Conversion | 0.81x | 0.86x | 0.83x | 0.92x | 0.94x | 0.79x | 0.76x | 1.07x | 1.06x | 0.89x |
Related:CLRB Dividend History·CLRB Revenue History·CLRB Price History·CLRB P/E History·CLRB Financial Ratios·CLRB Institutional Holders
CLRB SEC Filings & Documents
Cellectar Biosciences, Inc. (CLRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLRB Frequently Asked Questions
Cellectar Biosciences, Inc. (CLRB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cellectar Biosciences, Inc. (CLRB) grew revenue by 0.0% over the past year. Growth has been modest.
Cellectar Biosciences, Inc. (CLRB) reported a net loss of $20.8M for fiscal year 2025.
Dividend & Returns
Cellectar Biosciences, Inc. (CLRB) has a return on equity (ROE) of -180.0%. Negative ROE indicates the company is unprofitable.
Cellectar Biosciences, Inc. (CLRB) had negative free cash flow of $18.6M in fiscal year 2025, likely due to heavy capital investments.